Key Highlights
- Paige transitions its AI solutions to a standalone offering compatible with other digital pathology platforms.
- Razik Yousfi appointed as CTO & CEO to lead this new initiative.
- Focus on expanding access to Paige’s diagnostic AI through global partnerships.
Source: Business Wire
Notable Quotes
- “By focusing our efforts on advancing AI for cancer care and expanding the accessibility of our diagnostic AI applications, we will set new standards and profoundly impact patient treatments and outcomes.” — Razik Yousfi, CTO and CEO at Paige
- “Having built the world’s strongest diagnostic AI solutions, we now want to make them available to cancer patients globally through partnerships with other digital pathology providers.” — Peter Hamilton, General Manager of Diagnostics at Paige
SoHC's Take
Paige’s strategic shift represents a significant advancement in the integration of AI within oncology and pathology. By decoupling their diagnostic AI from their proprietary platform, they open doors for broader adoption across the digital pathology landscape. This move, under the guidance of Razik Yousfi, signals Paige’s commitment to making AI-driven cancer care more accessible and impactful on a global scale, setting new benchmarks in diagnostic precision and patient outcomes.
